Arthrosi ARTHROSI TO PRESENT POSITIVE PHASE 2 DATA FOR ITS NOVEL SELECTIVE URAT1 INHIBITOR AR882 IN PATIENTS WITH TOPHACEOUS GOUT AT ACR CONVERGENCE 2023 Posted on 2023-11-072024-03-13 by maxproadmin More >>
Arthrosi Arthrosi Therapeutics AR882 Prepares to Enter into Global Phase 3 Study Posted on 2023-08-182023-09-28 by maxproadmin More >>
Arthrosi ARTHROSI SECURES $75M IN SERIES D FINANCING Posted on 2023-07-112023-09-28 by maxproadmin More >>
Arthrosi ARTHROSI ANNOUNCES POSITIVE TOPLINE RESULTS FOR AR882 PHASE 2B STUDY Posted on 2023-01-052023-05-30 by maxproadmin More >>
Arthrosi Arthrosi completes AR882 phase 2B study enrollment Posted on 2022-08-232022-11-24 by maxproadmin More >>
Arthrosi Arthrosi Presents AR882 Posters at ACR 2021 Posted on 2021-11-022021-11-03 by maxproadmin More >>
Arthrosi Arthrosi Appoints Robert Thomas Keenan MD, MPH, MBA as Chief Medical Officer Posted on 2021-10-122021-11-03 by maxproadmin More >>
Arthrosi Arthrosi Establishes Joint Venture in China to Accelerate Development of Innovative Drug Portfolio Posted on 2021-08-172021-12-03 by maxproadmin More >>
Arthrosi Arthrosi Therapeutics, Inc. Announces Impressive Phase 2a Study Results for Gout Patients Posted on 2021-06-012021-07-26 by maxproadmin More >>
Arthrosi Arthrosi’s New Molecule AR882 for Gout Shows Blockbuster-Potential Posted on 2021-05-102021-06-03 by maxproadmin More >>
